Evaxion to present at several conferences during the second half of 2025
Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-powered vaccine development, has announced its participation in multiple scientific and investor conferences across the US, Europe, and Asia during H2 2025.
The company's Chief Scientific Officer and interim CEO Birgitte Rønø highlighted that their two-year clinical data for the personalized cancer vaccine EVX-01 has been selected for oral presentation at the ESMO congress in October. The conference schedule includes prestigious events such as the Vaccine Congress in Kyoto, HC Wainwright Global Investment Conference in New York, and the World Vaccine Congress Europe in Amsterdam.
Evaxion (NASDAQ: EVAX), azienda TechBio in fase clinica specializzata nello sviluppo di vaccini potenziati dall'IA, ha annunciato la sua partecipazione a numerosi convegni scientifici e incontri con investitori in Nord America, Europa e Asia nel secondo semestre del 2025.
La Chief Scientific Officer e interim CEO Birgitte Rønø ha evidenziato che i dati clinici biennali sul vaccino oncologico personalizzato EVX-01 sono stati selezionati per una presentazione orale al congresso ESMO in ottobre. Il calendario delle conferenze include appuntamenti di rilievo come il Vaccine Congress di Kyoto, l'HC Wainwright Global Investment Conference a New York e il World Vaccine Congress Europe ad Amsterdam.
Evaxion (NASDAQ: EVAX), compañía TechBio en fase clínica centrada en el desarrollo de vacunas impulsadas por IA, ha anunciado su participación en múltiples conferencias científicas y para inversores en EE. UU., Europa y Asia durante la segunda mitad de 2025.
La Chief Scientific Officer y CEO interina Birgitte Rønø destacó que los datos clínicos de dos años de la vacuna personalizada contra el cáncer EVX-01 han sido seleccionados para una presentación oral en el congreso ESMO en octubre. El programa de conferencias incluye eventos destacados como el Vaccine Congress en Kioto, la HC Wainwright Global Investment Conference en Nueva York y el World Vaccine Congress Europe en Ámsterdam.
Evaxion (NASDAQ: EVAX)는 AI 기반 백신 개발에 주력하는 임상 단계의 테크바이오 기업으로, 2025년 하반기 동안 미국·유럽·아시아에서 열리는 여러 학술 및 투자자 콘퍼런스에 참가한다고 발표했습니다.
회사의 최고과학책임자 겸 임시 CEO Birgitte Rønø는 개인 맞춤형 암 백신 EVX-01에 대한 2년 임상 데이터가 10월 ESMO 총회에서 구두 발표로 선정되었다고 밝혔습니다. 컨퍼런스 일정에는 교토의 Vaccine Congress, 뉴욕의 HC Wainwright Global Investment Conference, 암스테르담의 World Vaccine Congress Europe 등 권위 있는 행사가 포함되어 있습니다.
Evaxion (NASDAQ: EVAX), entreprise TechBio en phase clinique axée sur le développement de vaccins assistés par IA, a annoncé sa participation à plusieurs conférences scientifiques et auprès d'investisseurs aux États-Unis, en Europe et en Asie au second semestre 2025.
La Chief Scientific Officer et CEO par intérim Birgitte Rønø a souligné que les données cliniques sur deux ans du vaccin personnalisé contre le cancer EVX-01 ont été retenues pour une présentation orale au congrès ESMO en octobre. Le calendrier des conférences inclut des événements prestigieux tels que le Vaccine Congress à Kyoto, la HC Wainwright Global Investment Conference à New York et le World Vaccine Congress Europe à Amsterdam.
Evaxion (NASDAQ: EVAX), ein TechBio-Unternehmen in der klinischen Phase, das sich auf KI-gestützte Impfstoffentwicklung spezialisiert, hat seine Teilnahme an mehreren wissenschaftlichen und Anlegerkonferenzen in den USA, Europa und Asien für das zweite Halbjahr 2025 angekündigt.
Die Chief Scientific Officer und interimistische CEO Birgitte Rønø betonte, dass die zweijährigen klinischen Daten zum personalisierten Krebsimpfstoff EVX-01 für eine mündliche Präsentation beim ESMO-Kongress im Oktober ausgewählt wurden. Der Konferenzplan umfasst angesehene Veranstaltungen wie den Vaccine Congress in Kyoto, die HC Wainwright Global Investment Conference in New York und den World Vaccine Congress Europe in Amsterdam.
- None.
- None.
- Evaxion will provide scientific and company updates at numerous conferences in both the US, Europe and Asia during the coming months
COPENHAGEN, Denmark, August 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting data and company updates at numerous scientific and investor conferences throughout the second half of 2025.
Further to presenting, Evaxion will engage with stakeholders, including potential partners, at the conferences. With events taking place in both the US, Europa and Asia, we will have many opportunities to liaise with global audiences as part of our strategy to identify potential partners and opportunities for both business partnerships and scientific collaborations.
“As a scientific and innovative company, it is very important for us to present our data and discoveries and engage with the external communities. We are excited to be invited to numerous important conferences and especially thrilled to have the two-year clinical data for our personalized cancer vaccine EVX-01 selected for oral presentation at the ESMO congress in October,” says Birgitte Rønø, CSO and interim CEO of Evaxion.
In addition to the events listed below, Evaxion will be participating, but not presenting, at additional conferences to further boost our stakeholder engagement. Also, we may present at additional events not planned or confirmed yet. Please visit our website for more information.
Evaxion conference participation September-December 2025:
19th Vaccine Congress, September 7-10 - Kyoto
HC Wainwright Global Investment Conference, September 8-10 - New York
6th ESCMID Conference on vaccines, September 10-13 - Lisbon
Lake Street Best Ideas Growth Conference, September 12 - New York
HC Andersen seminar, September 18 - Copenhagen
Vax On Vaccines: Present and future in oncology, October 1 - Milan
BiotechX Europe, October 6-8 - Basel
World Vaccine Congress Europe, October 14-16 - Amsterdam
European Society for Medical Oncology (ESMO) Congress 2025, October 17-21 - Berlin
Society for Immunotherapy of Cancer (SITC) 2025, November 5-9 - National Harbor
Vaccines Summit, November 13-15 - Boston
NextGen Omics, November 13-14 - London
Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
About Evaxion
Evaxion is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
When will Evaxion (EVAX) present their EVX-01 cancer vaccine data at ESMO 2025?
Which major conferences will Evaxion (EVAX) attend in H2 2025?
Who is the current CEO of Evaxion Biotech (EVAX)?
What is Evaxion's (EVAX) main business focus?
